Welcome to the international HTA database

Showing [21894 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
1993	Health Council of the Netherlands Gezondheidsraad (GR)	Testing and prediction
2006	Agency for Healthcare Research and Quality (AHRQ)	Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure
2012	Medical Services Advisory Committee (MSAC)	Testing for BRAF mutation in patients with metastatic melanoma for access to (1c) vemurafenib
2018	Penn Medicine Center for Evidence-based Practice (CEP)	Testing for clostridium difficile in oncology patients
2007	Agency for Healthcare Research and Quality (AHRQ)	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
2013	Medical Services Advisory Committee (MSAC)	Testing for epidermal growth factor receptor (EGFR) status in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) for access to erlotinib
2007	Haute Autorite de sante (HAS)	Testing for FV Leiden and FII 20210G>A mutations
2007	Haute Autorite de sante (HAS)	Testing for Heparin-Induced thrombocytopenia
2012	Medical Services Advisory Committee (MSAC)	Testing for HER-2 status in advanced or metastatic breast cancer (stage IIIA-IV) to access lapatinib
2006	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Testing for HER2 positive breast cancer: a cost-effectiveness analysis
2007	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 positivity in patients diagnosed with breast cancer to determine eligibility for treatment with trastuzumab
2012	Medical Services Advisory Committee (MSAC)	Testing for HER2 status in gastric cancer for access to trastuzumab
2003	ECRI	Testing for HER2/NEU status in breast cancer
2017	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2015	Adelaide Health Technology Assessment (AHTA)	Testing for hereditary mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
2023	Ontario Health	Testing for homologous recombination deficiency in patients diagnosed with ovarian cancer
2013	Medical Services Advisory Committee (MSAC)	Testing for V600 status in patients with locally advanced or metastatic melanoma for access to appropriate therapies
2013	Agency for Healthcare Research and Quality (AHRQ)	Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment
2021	NIHR Health Technology Assessment programme	Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2003	Finnish Office for Health Care Technology Assessment (Finohta)	Testing the regional application of information technology (IT) in social welfare and health care (Satakunta Macropilot project)
2005	NIHR Health Technology Assessment programme	Testing treatments on animals: relevance to humans
2014	Health Quality Ontario (HQO)	Testing vitamin B12 levels in neuropathy, alopecia, dizziness, and fatigue: a rapid review
2013	HAYES, Inc.	Testosterone for low sexual desire in nonsurgically postmenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in premenopausal women
2009	HAYES, Inc.	Testosterone for low sexual desire in surgically postmenopausal women
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Testosterone reference ranges for gender diverse individuals
2002	The Swedish Council on Health Technology Assessment (SBU)	Testosterone replacement in men with age-related hormone deficiency - early assessment briefs (ALERT)
2011	Penn Medicine Center for Evidence-based Practice (CEP)	Tests for early diagnosis of sepsis
2022	Norwegian Institute of Public Health (NIPH)	Tests for the detection of NTRK gene fusions in patients with locally advanced or metastatic solid tumours
2003	Health Council of the Netherlands Gezondheidsraad (GR)	Tetanus prophylaxis in injuries
2006	Health Council of the Netherlands Gezondheidsraad (GR)	Tetrachloroethane; Health-based recommended occupational exposure limit
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Texture analysis of Radiological images (TexRAD) for lung cancer assessment
2021	Institute for Clinical and Economic Review (ICER)	Tezepelumab for severe asthma
2014	NIHR Horizon Scanning Centre (NIHR HSC)	TH-302 in combination with doxorubicin for locally advanced or metastatic, unresectable soft tissue sarcoma – first line
1999	ECRI	Thalamic stimulation for Parkinson's disease
1996	Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT)	Thalamic stimulation for tremor treatment (systematic review, primary research, expert panel)
2000	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Thalamus stimulation for the treatment of pharmacotherapy resistant tremor - primary research
2009	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy
2002	NIHR Horizon Scanning Centre (NIHR HSC)	Thalidomide for multiple myeloma - horizon scanning review
2004	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Thalidomide for the treatment of multiple myeloma
2010	Health Council of the Netherlands Gezondheidsraad (GR)	The 'thousand-dollar genome': an ethical exploration
1999	Health Council of the Netherlands Gezondheidsraad (GR)	The 1998 reports of the Health Council of the Netherlands (Executive summaries)
2020	European Network for Health Technology Assessment (EUnetHTA)	The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular disease risk
2014	NIHR Health Technology Assessment programme	The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for acute severe asthma
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	The ABCD2 scoring system for transient ischemic attacks: a review of the diagnostic accuracy and predictive value
2004	Centre for Clinical Effectiveness (CCE)	The accuracy of bioelectric impedance analysis in assessing fat free mass in patients with chronic obstructive pulmonary disease
2008	Institute of Health Economics (IHE)	The Actim™ Partus versus the TLIIQ® System as rapid response tests to aid in diagnosing preterm labour in symptomatic women
2021	NIHR Health Technology Assessment programme	The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2017	NIHR Health Technology Assessment programme	The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
2005	NIHR Health Technology Assessment programme	The analysis of critical incidents and adverse events in medicine - methodological research
2013	Agency for Healthcare Research and Quality (AHRQ)	The ankle brachial index for peripheral artery disease screening and cardiovascular disease prediction in asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force
2016	NIHR Health Technology Assessment programme	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysis
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis
2014	Health Quality Ontario (HQO)	The appropriate use of neuroimaging in the diagnostic work-up of dementia: OHTAC recommendation
2021	NIHR Health Technology Assessment programme	The Arabin pessary to prevent preterm birth in women with a twin pregnancy and a short cervix: the STOPPIT 2 RCT
2001	TNO	The artificial heart, a realistic alternative? Simulation model for dynamics of waiting lists
2017	NIHR Health Technology Assessment programme	The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal
2009	Health Services Assessment Collaboration (HSAC)	The assessment and management of chronic pain in children and adolescents: an overview of selected literature.
1999	Alberta Heritage Foundation for Medical Research (AHFMR)	The assessment of telemedicine: general principles and a systematic review
1999	Finnish Office for Health Care Technology Assessment (Finohta)	The assessment of telemedicine. General principles and a systematic review
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	The association between obesity, aboriginal or indigenous people, indian or alaskan natives living in North America and residence in remote locations and severe outcomes with seasonal and pandemic influenza: a review of the clinical evidence
2020	NIHR Health Technology Assessment programme	The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study
2017	NIHR Health Technology Assessment programme	The Asymptomatic Carotid Surgery Trial-2 (ACST-2): an ongoing randomised controlled trial comparing carotid endarterectomy with carotid artery stenting to prevent stroke
2002	Agency for Healthcare Research and Quality (AHRQ)	The autopsy as an outcome and performance measure
2006	Health Council of the Netherlands Gezondheidsraad (GR)	The benefit of HLA-matching in kidney transplantation
2002	Centre for Clinical Effectiveness (CCE)	The benefit of moving antenatal classes out of the hospital into the community
2002	Health Council of the Netherlands Gezondheidsraad (GR)	The benefit of population screening for breast cancer with mammography - Systematic review, expert panel
2022	NIHR Health Technology Assessment programme	The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health
2007	NIHR Health Technology Assessment programme	The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient adherence
2001	Centre for Technology Assessment at the Swiss Science and Technology Council (TA-SWISS)	The birth of a new type of treatment. Cells extracted from other species for use in treating diseases in humans. (Short version of the TA study 'Xenotransplantation of cells')
2015	NIHR Health Services and Delivery Research programme	The Birthplace in England national prospective cohort study: further analyses to enhance policy and service delivery decision-making for planned place of birth
2000	Centre for Clinical Effectiveness (CCE)	The bleeding patterns which can occur with long term hormone replacement therapy (HRT) and how they correlate with endometrial pathology
2005	NIHR Health Technology Assessment programme	The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis
2005	NIHR Health Technology Assessment programme	The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis
2023	Agency for Care Effectiveness (ACE)	The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2015	NIHR Health Technology Assessment programme	The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis
2016	NIHR Health Services and Delivery Research programme	The care of dying people in nursing homes and intensive care units: a qualitative mixed-methods study
2005	NIHR Health Technology Assessment programme	The causes and effects of socio-demographic exclusions from clinical trials
2001	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	The challenges of early assessment: leukotriene receptor antagonists
2019	NIHR Health Services and Delivery Research programme	The changing general practitioner workforce: the development of policies and strategies aimed at retaining experienced GPs and those taking a career break in direct patient care (ReGROUP)
2014	NIHR Health Technology Assessment programme	The clinical and cost effectiveness of ablative therapies in the management of liver metastases: systematic review and economic modelling study
2005	West Midlands Health Technology Assessment Collaboration (WMHTAC)	The clinical and cost effectiveness of biventricular pacing for patients with severe heart failure: addendum report ; January 2005 [updated January 2006]
2014	NIHR Health Technology Assessment programme	The clinical and cost effectiveness of brief intervention for excessive alcohol consumption among people attending sexual health clinics: a randomised controlled trial (SHEAR)
2006	West Midlands Health Technology Assessment Collaboration (WMHTAC)	The clinical and cost effectiveness of counselling interventions for heavy alcohol drinkers to reduce domestic violence
2005	NIHR Health Technology Assessment programme	The clinical and cost effectiveness of drotecogin alfa-activated (Xigris) for the treatment of severe sepsis or septic shock in adults - NICE Technology Assessment Report
2008	Quality Improvement Scotland (NHS QIS )	The clinical and cost effectiveness of hyperbaric oxygen therapy (HBOT)
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2007	Quality Improvement Scotland (NHS QIS )	The clinical and cost effectiveness of screening for meticillin-resistant Staphylococcus aureus (MRSA)
2008	Quality Improvement Scotland (NHS QIS )	The clinical and cost effectiveness of surgical insertion of grommets for otitis media with effusion (glue ear) in children
2010	NIHR Health Technology Assessment programme	The clinical and cost effectiveness of testing for cytochrome P450 polymorphisms in patients treated with antipsychotics: a systematic review and economic evaluation
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2007	Quality Improvement Scotland (NHS QIS )	The clinical and cost effectiveness of thromboelastography/thromboelastometry
2004	NIHR Health Technology Assessment programme	The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
2008	Institute of Applied Health Sciences (IAHS)	The clinical and cost-effectiveness of computed tomography as an alternative to angiography in investigation of coronary artery disease
2013	NIHR Health Technology Assessment programme	The clinical and cost-effectiveness of different treatment pathways for neuropathic pain (NP)
2006	NIHR Health Technology Assessment programme	The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
2007	West Midlands Health Technology Assessment Collaboration (WMHTAC)	The clinical and cost-effectiveness of immunoprophylaxis against respiratory syncytial virus with palivizumab in children